Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%.

Looking at these two biotech stocks from a long-term perspective, is Invitae now the better buy? Or is Vertex's strong run this year likely to extend into 2023?

Vertex Pharmaceuticals has had a record year in revenue, thanks to its cystic fibrosis (CF) treatments. The biotech company specializes in small molecule therapies to treat CF, plus a host of other diseases. 

Continue reading

Source Fool.com